{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:35:26Z","timestamp":1790735726027,"version":"4.1.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":2948,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mucosalimmunology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mucosal Immunology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/mi.2013.73","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T08:16:46Z","timestamp":1380701806000},"page":"6-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":291,"title":["New targets for mucosal healing and therapy in inflammatory bowel diseases"],"prefix":"10.1016","volume":"7","author":[{"given":"M F","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mi.2013.73_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0602-567","article-title":"The role of Th1\/Th2 polarization in mucosal immunity","volume":"8","author":"Neurath","year":"2002","journal-title":"Nat. Med."},{"key":"10.1038\/mi.2013.73_bib3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1038\/mi.2013.73_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ibd.21417","article-title":"Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts","volume":"17","author":"Peyrin-Biroulet","year":"2011","journal-title":"Inflamm. Bowel Dis"},{"key":"10.1038\/mi.2013.73_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1038\/mi.2013.73_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000341692","article-title":"Colitis and colorectal cancer","volume":"30","author":"Foersch","year":"2012","journal-title":"Dig. Dis."},{"issue":"Suppl 2","key":"10.1038\/mi.2013.73_bib7","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/S1873-9946(12)60502-9","article-title":"Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life","volume":"6","author":"Hommes","year":"2012","journal-title":"J. Crohn's Colitis"},{"key":"10.1038\/mi.2013.73_bib8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: a systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrgastro.2009.203","article-title":"Clinical implications of mucosal healing for the management of IBD","volume":"7","author":"Pineton de Chambrun","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1038\/mi.2013.73_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cgh.2011.03.009","article-title":"We once were blind and now we see: Is it time to treat ulcerative colitis to achieve mucosal healing?","volume":"9","author":"Rubin","year":"2011","journal-title":"Clin. Gastroenterol Hepatol"},{"key":"10.1038\/mi.2013.73_bib14","unstructured":"Colombel, J.F. et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. in press (2013)."},{"key":"10.1038\/mi.2013.73_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ibd.21316","article-title":"Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing","volume":"17","author":"Krishnan","year":"2011","journal-title":"Inflamm. Bowel Dis"},{"key":"10.1038\/mi.2013.73_bib16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/ibd.20499","article-title":"Galectin-2 and -4, but not galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism","volume":"14","author":"Paclik","year":"2008","journal-title":"Inflamm. Bowel Dis"},{"key":"10.1038\/mi.2013.73_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3748\/wjg.14.348","article-title":"Epithelial restitution and wound healing in inflammatory bowel disease","volume":"14","author":"Sturm","year":"2008","journal-title":"World J. Gastroenterol"},{"key":"10.1038\/mi.2013.73_bib18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0016-5085(93)90136-Z","article-title":"Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta","volume":"105","author":"Dignass","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1172\/JCI117332","article-title":"Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway","volume":"94","author":"Dignass","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"Part 5","key":"10.1038\/mi.2013.73_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1042\/BST0330891","article-title":"Rho GTPases and the control of cell behaviour","volume":"33","author":"Hall","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1038\/mi.2013.73_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/labinvest.3700595","article-title":"Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia","volume":"87","author":"Moyer","year":"2007","journal-title":"Lab. Invest."},{"key":"10.1038\/mi.2013.73_bib22","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.1074\/jbc.M805289200","article-title":"CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells","volume":"284","author":"Vongsa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1038\/mi.2013.73_bib23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3748\/wjg.v17.i17.2161","article-title":"Wound healing of intestinal epithelial cells","volume":"17","author":"Iizuka","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/gut.38.5.687","article-title":"Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta","volume":"38","author":"Dignass","year":"1996","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib25","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1084\/jem.20082683","article-title":"STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing","volume":"206","author":"Pickert","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature05698","article-title":"Epithelial NEMO links innate immunity to chronic intestinal inflammation","volume":"446","author":"Nenci","year":"2007","journal-title":"Nature"},{"key":"10.1038\/mi.2013.73_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1038\/mi.2013.73_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"key":"10.1038\/mi.2013.73_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1073\/pnas.0803343106","article-title":"Efficient colonic mucosal wound repair requires Trem2 signaling","volume":"106","author":"Seno","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1038\/mi.2013.73_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ajpath.2012.06.016","article-title":"P53 mediates TNF-induced epithelial cell apoptosis in IBD","volume":"181","author":"Goretsky","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1038\/mi.2013.73_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/emmm.201100192","article-title":"Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation","volume":"4","author":"Gilbert","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1038\/mi.2013.73_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2007.145094","article-title":"Regulation of intestinal barrier function by signal transducer and activator of transcription 5b","volume":"58","author":"Han","year":"2009","journal-title":"Gut"},{"issue":"Part 1","key":"10.1038\/mi.2013.73_bib33","first-page":"G809","article-title":"Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor","volume":"274","author":"Goke","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1038\/mi.2013.73_bib34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2013.04.011","article-title":"TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis","volume":"145","author":"Su","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ibd.21072","article-title":"Granulocyte\u2013macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing","volume":"16","author":"Bernasconi","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbadis.2012.11.017","article-title":"Regulation of wound healing and organ fibrosis by toll-like receptors","volume":"1832","author":"Huebener","year":"2013","journal-title":"Biochim Biophys. Acta"},{"key":"10.1038\/mi.2013.73_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.gastro.2009.03.007","article-title":"Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency","volume":"137","author":"Podolsky","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib38","doi-asserted-by":"crossref","first-page":"22332","DOI":"10.1074\/jbc.M901619200","article-title":"TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury","volume":"284","author":"Ey","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1038\/mi.2013.73_bib39","doi-asserted-by":"crossref","first-page":"G1055","DOI":"10.1152\/ajpgi.00328.2004","article-title":"Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis","volume":"288","author":"Fukata","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1038\/mi.2013.73_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ncb1500","article-title":"Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells","volume":"8","author":"Lee","year":"2006","journal-title":"Nat. Cell. Bio.l"},{"key":"10.1038\/mi.2013.73_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MOG.0b013e3280118272","article-title":"Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homoeostasis","volume":"23","author":"Lee","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/srep00574","article-title":"TLR9 is important for protection against intestinal damage and for intestinal repair","volume":"2","author":"Rose","year":"2012","journal-title":"Scientific Rep."},{"key":"10.1038\/mi.2013.73_bib43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1172\/JCI22996","article-title":"Toll-like receptor 9-induced type I IFN protects mice from experimental colitis","volume":"115","author":"Katakura","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1038\/mi.2013.73_bib44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1053\/j.gastro.2003.11.019","article-title":"Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis","volume":"126","author":"Rachmilewitz","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib45","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/gast.2002.32994","article-title":"Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis","volume":"122","author":"Rachmilewitz","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib46","doi-asserted-by":"crossref","first-page":"18129","DOI":"10.1073\/pnas.0505256102","article-title":"Reduced Paneth cell alpha-defensins in ileal Crohn's disease","volume":"102","author":"Wehkamp","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1038\/mi.2013.73_bib47","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/j.gastro.2006.09.006","article-title":"Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing","volume":"131","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib48","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/jcb.21787","article-title":"Human beta defensin 2 promotes intestinal wound healing in vitro","volume":"104","author":"Otte","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1038\/mi.2013.73_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bpg.2003.10.009","article-title":"Microbial\u2013gut interactions in health and disease. Immune responses","volume":"18","author":"Pickard","year":"2004","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"Part 5","key":"10.1038\/mi.2013.73_bib50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1113\/jphysiol.2011.224568","article-title":"Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics","volume":"590","author":"Hering","year":"2012","journal-title":"J. Physiol."},{"key":"10.1038\/mi.2013.73_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ibd.20539","article-title":"Intestinal barrier dysfunction in inflammatory bowel diseases","volume":"15","author":"McGuckin","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib52","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/ars.2011.3892","article-title":"Epithelial barriers in intestinal inflammation","volume":"15","author":"John","year":"2011","journal-title":"Antioxidants Redox Signal."},{"key":"10.1038\/mi.2013.73_bib53","doi-asserted-by":"crossref","first-page":"G970","DOI":"10.1152\/ajpgi.00183.2012","article-title":"Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells","volume":"304","author":"Fischer","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1038\/mi.2013.73_bib54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/gut.2003.036632","article-title":"Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment","volume":"53","author":"Zeissig","year":"2004","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MCG.0b013e3182688e73","article-title":"Mucin function in inflammatory bowel disease: an update","volume":"47","author":"Boltin","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1440-1746.2011.06909.x","article-title":"Mucins in inflammatory bowel diseases and colorectal cancer","volume":"27","author":"Sheng","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"Suppl 1","key":"10.1038\/mi.2013.73_bib58","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1073\/pnas.1006451107","article-title":"The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host\u2013microbial interactions","volume":"108","author":"Johansson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1038\/mi.2013.73_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/gmic.1.1.10470","article-title":"The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria","volume":"1","author":"Hansson","year":"2010","journal-title":"Gut Microbes"},{"key":"10.1038\/mi.2013.73_bib60","doi-asserted-by":"crossref","first-page":"431231","DOI":"10.1155\/2013\/431231","article-title":"Mucosal barrier in ulcerative colitis and Crohn's disease","volume":"2013","author":"Dorofeyev","year":"2013","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1038\/mi.2013.73_bib61","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000320407","article-title":"Phosphatidylcholine (lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis?","volume":"28","author":"Stremmel","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1038\/mi.2013.73_bib62","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gut.2004.052316","article-title":"Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis","volume":"54","author":"Stremmel","year":"2005","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10400","article-title":"Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis","volume":"477","author":"Gunther","year":"2011","journal-title":"Nature"},{"key":"10.1038\/mi.2013.73_bib64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature01520","article-title":"Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin","volume":"422","author":"Salzman","year":"2003","journal-title":"Nature"},{"key":"10.1038\/mi.2013.73_bib65","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2796.2012.02515.x","article-title":"Innate immune dysfunction in inflammatory bowel disease","volume":"271","author":"Gersemann","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1038\/mi.2013.73_bib67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/gut.2009.193177","article-title":"T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells","volume":"59","author":"Hofmann","year":"2010","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ibd.23019","article-title":"Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity","volume":"19","author":"Musch","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib69","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-2036.2006.02879.x","article-title":"Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin","volume":"23","author":"Prantera","year":"2006","journal-title":"Aliment. Pharmacol. Therap."},{"key":"10.1038\/mi.2013.73_bib71","first-page":"307","article-title":"Randomized controlled trials in prevention of postsurgical recurrence in Crohn's disease","volume":"7","author":"Papi","year":"2012","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1038\/mi.2013.73_bib72","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.coi.2012.08.001","article-title":"Common alleles that influence autophagy and the risk for inflammatory bowel disease","volume":"24","author":"Gardet","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1038\/mi.2013.73_bib73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1146\/annurev-immunol-020711-074948","article-title":"Autophagy and the immune system","volume":"30","author":"Kuballa","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1038\/mi.2013.73_bib74","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI44632","article-title":"Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae","volume":"121","author":"Chassaing","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"Suppl 3","key":"10.1038\/mi.2013.73_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000342588","article-title":"Inflammatory bowel disease: dysfunction of autophagy?","volume":"30","author":"Scharl","year":"2012","journal-title":"Dig. Dis."},{"key":"10.1038\/mi.2013.73_bib76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/labinvest.2011.156","article-title":"Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-alpha secretion","volume":"92","author":"Bringer","year":"2012","journal-title":"Lab. Invest."},{"key":"10.1038\/mi.2013.73_bib77","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1210\/me.2011-0068","article-title":"Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms","volume":"25","author":"Flammer","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"10.1038\/mi.2013.73_bib78","first-page":"1424","article-title":"Cyclosporin for severe ulcerative colitis: a user's guide","volume":"92","author":"Kornbluth","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"key":"10.1038\/mi.2013.73_bib80","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib81","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N.Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2249.1999.00753.x","article-title":"Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression","volume":"115","author":"Neurath","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1038\/mi.2013.73_bib83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2249.1999.01022.x","article-title":"Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis","volume":"118","author":"Hildner","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1038\/mi.2013.73_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/187152808784165207","article-title":"Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases","volume":"7","author":"Kaminuma","year":"2008","journal-title":"Inflamm. Allergy DrugTargets"},{"key":"10.1038\/mi.2013.73_bib85","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2012-02-404475","article-title":"NFAT control of innate immunity","volume":"120","author":"Fric","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mi.2013.73_bib86","doi-asserted-by":"crossref","unstructured":"Daniel, C, Gerlach, K, Vath, M, Neurath, M.F. & Weigmann, B. Nuclear factor of activated T cells\u2014a transcription factor family as critical regulator in lung and colon cancer. Int. J. Cancer (in press) (2013).","DOI":"10.1002\/ijc.28329"},{"key":"10.1038\/mi.2013.73_bib87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2008.170183","article-title":"Selective targeting of activated T cells in chronic intestinal inflammation","volume":"58","author":"Weigmann","year":"2009","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib88","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1038\/mi.2013.73_bib89","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4049\/jimmunol.176.1.640","article-title":"Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins","volume":"176","author":"Poppe","year":"2006","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib90","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2011.05.005","article-title":"ADAM17: a molecular switch to control inflammation and tissue regeneration","volume":"32","author":"Scheller","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1038\/mi.2013.73_bib91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","article-title":"Tumor necrosis factor signaling","volume":"10","author":"Wajant","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1038\/mi.2013.73_bib92","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl J. Med."},{"key":"10.1038\/mi.2013.73_bib93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14712598.2012.658770","article-title":"A review and expert opinion of the use of certolizumab for Crohn's disease","volume":"12","author":"Evans","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1038\/mi.2013.73_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gut.2009.191411","article-title":"Predicting the response to infliximab from trough serum levels","volume":"59","author":"Rutgeerts","year":"2010","journal-title":"Gut"},{"issue":"Suppl 4","key":"10.1038\/mi.2013.73_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.1999.00026.x","article-title":"Review article: the efficacy of infliximab in Crohn's disease\u2014healing of fistulae","volume":"13","author":"Present","year":"1999","journal-title":"Aliment. Pharmacol. Therap."},{"key":"10.1038\/mi.2013.73_bib98","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1038\/mi.2013.73_bib99","unstructured":"Sandborn, W.J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (in press) (2013)."},{"key":"10.1038\/mi.2013.73_bib100","unstructured":"Sandborn, W.J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (in press) (2013)."},{"key":"10.1038\/mi.2013.73_bib101","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1038\/mi.2013.73_bib103","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/CVI.05649-11","article-title":"Modulation of anti-tumor necrosis factor alpha (TNF-alpha) antibody secretion in mice immunized with TNF-alpha kinoid","volume":"19","author":"Assier","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1038\/mi.2013.73_bib104","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/apt.12284","article-title":"Review article: the role of anti-TNF in the management of ulcerative colitis\u2014past, present and future","volume":"37","author":"Danese","year":"2013","journal-title":"Aliment. Pharmacol. Therap."},{"key":"10.1038\/mi.2013.73_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Aliment. Pharmacol. Therap."},{"key":"10.1038\/mi.2013.73_bib106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib107","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn's disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MOG.0b013e328361f7f6","article-title":"Drug monitoring of biologics in inflammatory bowel disease","volume":"29","author":"Eser","year":"2013","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivoin vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib111","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib112","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib113","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib114","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib115","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1038\/mi.2013.73_bib116","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1016\/S0016-5085(12)62054-X","article-title":"Prediction of anti-TNF antibody responses in crohn's disease by endoscopic molecular imaging in vivo","volume":"142","author":"Atreya","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib117","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ibd.23023","article-title":"Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis","volume":"19","author":"Perrier","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib118","first-page":"CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","volume":"5","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1038\/mi.2013.73_bib119","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1L268","article-title":"Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis","volume":"42","author":"Plushner","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1038\/mi.2013.73_bib121","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"Fuss","year":"1996","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1741-7015-9-122","article-title":"Th17-related cytokines: new players in the control of chronic intestinal inflammation","volume":"9","author":"Monteleone","year":"2011","journal-title":"BMC Med."},{"key":"10.1038\/mi.2013.73_bib123","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.2174\/138161210794079164","article-title":"Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases","volume":"16","author":"De Nitto","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1038\/mi.2013.73_bib124","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1084\/jem.20081712","article-title":"Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation","volume":"206","author":"Kleinschek","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib126","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib127","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2008.10.018","article-title":"RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F","volume":"136","author":"Leppkes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib129","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2010.12.002","article-title":"Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases","volume":"140","author":"Hovhannisyan","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.gastro.2012.04.043","article-title":"Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis","volume":"143","author":"Sands","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib131","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/138945008784221116","article-title":"Signaling molecules: the pathogenic role of the IL-6\/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer","volume":"9","author":"Atreya","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1038\/mi.2013.73_bib132","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"10.1038\/mi.2013.73_bib133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib134","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1038\/mi.2013.73_bib135","doi-asserted-by":"crossref","first-page":"R1264","DOI":"10.1152\/ajpregu.2001.281.4.R1264","article-title":"Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production","volume":"281","author":"Siegmund","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1038\/mi.2013.73_bib136","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1084\/jem.20111106","article-title":"Involvement of interleukin-21 in the regulation of colitis-associated colon cancer","volume":"208","author":"Stolfi","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib137","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.20100410","article-title":"IL-27 promotes T cell-dependent colitis through multiple mechanisms","volume":"208","author":"Cox","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib138","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1074-7613(02)00453-3","article-title":"Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells","volume":"17","author":"Heller","year":"2002","journal-title":"Immunity"},{"key":"10.1038\/mi.2013.73_bib139","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1053\/j.gastro.2011.08.040","article-title":"Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice\u2014a pathway associated with ulcerative colitis","volume":"141","author":"Kawashima","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1038\/mi.2013.73_bib140","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/mi.2008.40","article-title":"The role of IL-13 and NK T cells in experimental and human ulcerative colitis","volume":"1","author":"Fuss","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1038\/mi.2013.73_bib141","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1038\/mi.2013.73_bib142","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib143","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib144","doi-asserted-by":"crossref","unstructured":"Mayer, L. et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut (in press) (2013).","DOI":"10.1136\/gutjnl-2012-303424"},{"key":"10.1038\/mi.2013.73_bib145","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gut.2009.179994","article-title":"A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease","volume":"59","author":"Dotan","year":"2010","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-012-0008-z","article-title":"Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future","volume":"27","author":"Fournier","year":"2013","journal-title":"BioDrugs"},{"key":"10.1038\/mi.2013.73_bib147","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib148","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4049\/jimmunol.161.6.3143","article-title":"IL-12 but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice","volume":"161","author":"Davidson","year":"1998","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib149","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","volume":"117","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib150","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib151","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156652412800620066","article-title":"Th17-related cytokines in inflammatory bowel diseases: friends or foes?","volume":"12","author":"Monteleone","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1038\/mi.2013.73_bib152","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/mi.2012.102","article-title":"Host-dependent control of early regulatory and effector T-cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis","volume":"6","author":"Valatas","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1038\/mi.2013.73_bib153","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.4049\/jimmunol.162.4.1884","article-title":"Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens","volume":"162","author":"Wirtz","year":"1999","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib154","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.MIB.0000194183.92671.b6","article-title":"Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody","volume":"12","author":"Fuss","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib155","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib156","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib157","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib158","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib159","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1038\/mi.2013.73_bib160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.184.1.241","article-title":"T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice","volume":"184","author":"Davidson","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib161","first-page":"6042","article-title":"CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice","volume":"63","author":"Erdman","year":"2003","journal-title":"Cancer Res."},{"key":"10.1038\/mi.2013.73_bib162","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","article-title":"Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group","volume":"119","author":"Fedorak","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib163","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1572-0241.2005.00356.x","article-title":"Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease","volume":"101","author":"Herrlinger","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1038\/mi.2013.73_bib164","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease","volume":"4","author":"Braat","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1038\/mi.2013.73_bib165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.chom.2013.05.013","article-title":"A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice","volume":"13","author":"Hayashi","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1038\/mi.2013.73_bib166","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ibd.22929","article-title":"Healing of intestinal inflammation by IL-22","volume":"18","author":"Mizoguchi","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib167","doi-asserted-by":"crossref","unstructured":"Leung, J.M. et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol. (in press) (2013).","DOI":"10.1038\/mi.2013.31"},{"key":"10.1038\/mi.2013.73_bib168","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1053\/j.gastro.2011.07.040","article-title":"Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis","volume":"141","author":"Wirtz","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib169","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20040685","article-title":"T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells","volume":"201","author":"Fahlen","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib170","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.4049\/jimmunol.177.9.5852","article-title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis","volume":"177","author":"Uhlig","year":"2006","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib171","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.0105-2896.2006.00423.x","article-title":"Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation","volume":"212","author":"Izcue","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1038\/mi.2013.73_bib172","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.2005.072801","article-title":"Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis","volume":"55","author":"Fantini","year":"2006","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib173","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib174","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"issue":"Suppl 1","key":"10.1038\/mi.2013.73_bib175","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1038\/mi.2008.55","article-title":"TGF-beta1 and Smad7 in the regulation of IBD","volume":"1","author":"Monteleone","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1038\/mi.2013.73_bib176","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","article-title":"Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis","volume":"131","author":"Boirivant","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib177","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2008.12.053","article-title":"Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression","volume":"136","author":"Fantini","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib178","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1038\/mi.2013.73_bib179","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/491183a","article-title":"Autoimmunity: the worm returns","volume":"491","author":"Weinstock","year":"2012","journal-title":"Nature"},{"key":"10.1038\/mi.2013.73_bib180","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2005.01.005","article-title":"Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial","volume":"128","author":"Summers","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1038\/mi.2013.73_bib181","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/gut.2004.041749","article-title":"Trichuris suis therapy in Crohn's disease","volume":"54","author":"Summers","year":"2005","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib182","doi-asserted-by":"crossref","first-page":"e23590","DOI":"10.1371\/journal.pone.0023590","article-title":"The transcriptome of Trichuris suis\u2014first molecular insights into a parasite with curative properties for key immune diseases of humans","volume":"6","author":"Cantacessi","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/mi.2013.73_bib183","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMe058212","article-title":"Selective adhesion-molecule therapy and inflammatory bowel disease\u2014a tale of Janus?","volume":"353","author":"Podolsky","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib184","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1038\/mi.2013.73_bib185","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib186","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/mi.2013.73_bib187","first-page":"123","article-title":"New and emerging treatments for ulcerative colitis: a focus on vedolizumab","volume":"7","author":"Gledhill","year":"2013","journal-title":"Biologics"},{"key":"10.1038\/mi.2013.73_bib188","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/mi.2013.73_bib189","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2012","journal-title":"Gut"},{"key":"10.1038\/mi.2013.73_bib190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis","volume":"20","author":"Thomas","year":"2012","journal-title":"Inflammopharmacology"},{"key":"10.1038\/mi.2013.73_bib191","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4049\/jimmunol.171.1.159","article-title":"CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile","volume":"171","author":"Papadakis","year":"2003","journal-title":"J. Immunol."},{"key":"10.1038\/mi.2013.73_bib192","doi-asserted-by":"crossref","unstructured":"Bamias, G, Clark, D.J. & Rivera-Nieves, J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr. Drug Targets advance online publication, 25 April 2013 (e-pub ahead of print).","DOI":"10.2174\/13894501113149990158"},{"key":"10.1038\/mi.2013.73_bib193","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.20011956","article-title":"The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease","volume":"195","author":"Neurath","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1038\/mi.2013.73_bib194","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"}],"container-title":["Mucosal Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/mi201373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mi201373","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922010182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922010182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mi201373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:23:17Z","timestamp":1761830597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933021922010182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":194,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1933021922010182"],"URL":"https:\/\/doi.org\/10.1038\/mi.2013.73","relation":{},"ISSN":["1933-0219"],"issn-type":[{"value":"1933-0219","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets for mucosal healing and therapy in inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"Mucosal Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mi.2013.73","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1038\/mi.2013.32","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 \u00a9 Society for Mucosal Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}